Abstract 8050: Sodium-Glucose Cotransporter-2 Inhibitors Increase Estimated Glomerular Filtration Rate Slope and Ameliorate Clinical Outcomes After Catheter Ablation in Atrial Fibrillation Patients with Heart Failure
Background: Treatment of sodium-glucose cotransporter 2 inhibitors (SGLT2is) has been demonstrated to decrease cardiovascular events in patients with heart failure (HF) regardless of ejection fraction. Moreover, SGLT2i treatment also prevented deterioration of renal function in those with chronic kidney disease (CKD...